Xrn2 as a determinant of sensitivity to dna damage

Abstract

The present disclosure is directed to methods of detecting XRN2 expression levels, copy number and mutation status, particularly in cancer cells. The methods permit physicians to tailor therapies to subject having certain genotypes/phenotypes, and to exclude therapies unlikely to be effective.